SEC Comment Letter 0000000000-23-000297 to ImmunityBio, Inc. (IBRX) (CIK 0001326110) (IBRX)
ImmunityBio, Inc. (IBRX) (CIK 0001326110)
Date: Jan. 11, 2023 · CIK: 0001326110 · Accession: 0000000000-23-000297
AI Filing Summary & Sentiment
File numbers found in text: 001-37507
Letter
United States securities and exchange commission logo January 11, 2023 David Sachs Chief Financial Officer ImmunityBio, Inc. 3530 John Hopkins Court San Diego, CA 92121 Re:ImmunityBio, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 1, 2022 File No. 001-37507 Dear David Sachs: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 11, 2023
David Sachs
Chief Financial Officer
ImmunityBio, Inc.
3530 John Hopkins Court
San Diego, CA 92121
Re:ImmunityBio, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed March 1, 2022
File No. 001-37507
Dear David Sachs:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences